Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Moderna's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Moderna's regulatory disclosures and financial reporting.
Moderna, Inc. Chief Financial Officer James M. Mock reported routine equity compensation activity involving restricted stock units and related tax withholding. He exercised 2,475 restricted stock units, which convert into common stock on a one-for-one basis, adding the same number of common shares.
To cover tax withholding obligations on this vesting, 1,197 common shares were withheld, at a value of $47.19 per share, rather than sold in the open market. Following these transactions, Mock directly holds 59,594 shares of common stock and 27,230 restricted stock units subject to future vesting under the disclosed schedule.
Moderna, Inc. Chief Legal Officer Shannon Thyme Klinger reported routine equity compensation activity. On June 1, 2026, restricted stock units (RSUs) converted into 2,165 shares of common stock on a one-for-one basis. In a related move, 1,047 common shares were withheld at $47.19 per share to satisfy tax withholding obligations in connection with the RSU vesting. These transactions reflect an exercise of derivative securities and associated tax-withholding dispositions, rather than open-market buying or selling.
Moderna, Inc. president Stephen Hoge reported routine equity compensation activity. He exercised 9,282 restricted stock units, which convert into common stock on a one-for-one basis, adding the same number of common shares.
In connection with this vesting, 4,488 shares were withheld at $47.19 per share to satisfy tax withholding obligations, a non‑market disposition. After these transactions, Hoge directly holds 1,483,848 shares of common stock and has 102,111 restricted stock units outstanding. Additional indirect common stock holdings are reported by a family trust and by Valhalla, LLC, with beneficial ownership of the trust shares disclaimed except for any pecuniary interest.
Moderna, Inc. Chief Financial Officer James M. Mock reported routine equity compensation activity involving restricted stock units. On May 27-28, 1,101 restricted stock units were exercised and converted into an equal number of common shares. To cover tax obligations on these vests, 533 common shares were withheld at prices of $47.03 and $47.61 per share, rather than sold on the open market. Following these transactions, Mock directly holds 58,316 shares of Moderna common stock, along with additional unvested restricted stock units.
Moderna, Inc.’s Chief Legal Officer Shannon Thyme Klinger reported routine equity compensation activity involving restricted stock units (RSUs). On May 27 and 28, 2026, RSUs converted into a total of 1,101 shares of common stock, reflecting scheduled vesting of prior awards.
Across the same two days, 533 shares of common stock were disposed of at prices of $47.03 and $47.61 per share, solely to satisfy tax withholding obligations associated with the RSU vests. These transactions are not open-market purchases or sales and leave Klinger with a continuing direct ownership stake in Moderna common stock.
Moderna, Inc. President Stephen Hoge reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. On May 27 and May 28, 2026, RSUs converted into a total of 2,047 shares of common stock, reflecting vesting of prior awards.
To cover tax obligations on these vestings, a total of 990 common shares were withheld at prices of $47.03 and $47.61 per share, categorized as tax-withholding dispositions rather than open-market sales. Following these transactions, Hoge directly held about 1,479,054 shares of Moderna common stock. The filing also reports 151,933 shares held by a trust for the benefit of his spouse and children and 4,116 shares held by Valhalla, LLC as indirect holdings, with beneficial ownership of the trust shares disclaimed except for any pecuniary interest.
Moderna, Inc. insider-related entities reported an option exercise and share sale. On May 21, 2026, Flagship Pioneering, LLC exercised stock options to acquire 9,263 shares of Moderna common stock at $19.15 per share, from options that were fully vested and set to expire on August 10, 2026.
That same day, Flagship Pioneering conducted an open-market sale of 9,263 shares of common stock at an average price of $46.84 per share, leaving 3,924 shares of common stock held indirectly by Flagship Pioneering afterward. The filing also shows 2,224,015 shares held directly by Noubar Afeyan and additional indirect holdings of 747,897 shares by Flagship Ventures Fund IV-Rx, L.P. and 3,880,328 shares by Flagship Ventures Fund IV, L.P. The reporting person is the ultimate control person of these entities and disclaims beneficial ownership except to the extent of his pecuniary interest.
Moderna, Inc. President Stephen Hoge reported an exercise-and-sale transaction in company stock. On May 15, 2026, he exercised stock options to acquire a total of 53,336 shares of common stock at an exercise price of $19.15 per share and sold 53,336 shares of common stock at an average price of $48.40 per share in open-market transactions. The filing notes that the reported transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025. After these transactions, Hoge directly held 1,477,997 shares of Moderna common stock, along with additional indirect holdings of 151,933 shares held by a family trust and 4,116 shares held through Valhalla, LLC.